ESC-HFA 2026 9 - 12 May 2026

Efficacy and safety of the microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT)

Authors :

Johann Bauersachs¹; Scott D Solomon ²; Stefan D Anker ³; Isabel Antorrena-Miranda ⁴; Rudolf A de Boer ⁵; Gerasimos Filippatos ⁶; Tim Friede ⁷; Wilfried Hauke ⁸; Piotr Ponikowski ⁹; Orly Vardeny ¹⁰; Rebecca Altschul ¹¹; Michael Gamborg ¹¹; Kasper Vinther ¹¹; Thomas Thum ⁸

Affiliations

View Details Hide Details

Keywords

Cardiovascular Disease

Congress oral presentation

PHASE 2 (RCT)

Search Science Hub

Are you a healthcare professional?

Efficacy and safety of the microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT)